

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

**Claim 1 (Currently Amended):** A protein comprising:

a first functional unit of a first complement regulatory protein, wherein the first functional unit exhibits complement regulating properties wherein the first functional unit comprises CCPs 2, 3 and 4 of DAF;

a first spacer sequence of at least about 200 amino acids ~~encoding a polypeptide that~~, wherein the first spacer sequence does not exhibit complement regulating properties, attached to the first functional unit; and

a second functional unit attached to the spacer sequence, selected from the group consisting of ~~polypeptides providing a functional unit of a second complement regulatory protein, polypeptides derived from an immunoglobulin, and polypeptides that enhance binding of the protein to an animal cell CCPs 8-10 of Complement Receptor 1 (CR1), CCPs 15-17 of CR1, poly peptides derived from Fc fragments of IgG4, and a lipid tail.~~

**Claim 2 (Currently Amended):** The protein of claim 1, additionally comprising a second spacer sequence of at least about 200 amino acids ~~encoding a polypeptide that does not exhibit complement regulating properties attached to the second function domain, and a third functional unit attached to the second spacer, wherein the third functional unit is selected from the group consisting of polypeptides~~

derived from an immunoglobulin Fc fragments of IgG4, and polypeptides that enhance binding of the protein to an animal cell a lipid tail.

**Claim 3 (Cancelled):**

**Claim 4 (Cancelled):**

**Claim 5 (Previously Presented):** The protein of claim 1, wherein the spacers are selected from the group consisting of substantially all of the amino acids of CCPs 4-7 of CR1, and substantially all of the amino acids of CCPs 11-14 of CR1.

**Claim 6 (Cancelled)**

**Claim 7 (Currently Amended):** The protein of claim 6 1, additionally compromising a second spacer comprising substantially all of the amino acids of CCPs 4-5 of CR1, and a third functional unit selected from the group consisting of CCPs 8-10 of CR1, CCPs 1-4 of MCP, and polypeptides derived from IgG4 Fc fragments of IgG4.

**Claim 8 (Withdrawn):** A polynucleotide encoding the protein of claim 6.

**Claim 9 (Withdrawn):** A polynucleotide encoding the protein of claim 7.

**Claim 10 (Withdrawn):** A polynucleotide encoding the protein of claim 1.

**Claim 11 (Withdrawn):** A vector comprising the polynucleotide of claim 10.

**Claim 12 (Currently Amended):** A protein having an amino acid sequence  
that is at least 95 percent sequence homology homologous to a protein selected  
from the group consisting of proteins having the sequence of SEQ ID NO: 13, SEQ  
ID NO: 15, SEQ ID NO: 19, and SEQ ID NO: 23.

**Claim 13 (Withdrawn):** A polynucleotide encoding the protein of claim 12.

**Claim 14 (Currently Amended):** A method of regulating inhibiting  
complement activity comprising administering an effective amount of protein ~~of claim~~  
to a mammal the protein having an amino acid sequence that is at least 95 percent  
homologous to a protein selected from the group consisting of proteins having the  
sequence of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 19, and SEQ ID NO: 23.

**Claim 15 (Previously Presented):** The method of claim 14, wherein the  
mammal is a human.

**Claim 16 (Cancelled)**

**Claim 17 (Cancelled)**

**Claim 18 (Cancelled)**

**Claim 19 (New):** The method of claim 14, the protein being selected from the group consisting of proteins having the sequence of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO:19, and SEQ ID NO:23.

**Claim 20 (New):** The method of claim 14, the protein being selected from the group consisting of proteins having the sequence of SEQ ID NO: 13 and SEQ ID NO: 15.